IDB

Innovative Drug Biotech Limited is a Hong Kong-based biotechnology company primarily focused on the research, development, and commercialization of innovative pharmaceutical products, particularly in the field of metabolic diseases. The company's flagship project is an oral insulin formulation, currently in Phase 3 clinical trials, which aims to provide a non-invasive and more convenient alternative to traditional insulin injections for patients with Type 2 diabetes. In addition to its core biotech R&D, the company maintains business segments involved in the trading of beauty and sanitary products and strategic investment holdings. Listed on the Hong Kong Stock Exchange, Innovative Drug Biotech primarily targets the healthcare market in the Greater China region. The company leverages its clinical pipeline and distribution networks to address significant unmet medical needs in endocrinology.